| 1. |
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study[J]. Ann Intern Med, 1995; 123(10): 754-762.
|
| 2. |
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotension-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group[J]. N Engl J Med, 1993; 329(20): 1456-1462.
|
| 3. |
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group[J]. N Engl J Med, 1996; 334(15): 939-945.
|
| 4. |
The GISEN Group(Gruppo Itailiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuic, non-diabetic nephropathy[J]. Lancet, 1997; 349(9069): 1857-1863.
|
| 5. |
Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy[J]. Lancet, 1998; 352(9136): 1252-1256.
|
| 6. |
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria[J]. Lancet, 1999; 354(9176): 359-364.
|
| 7. |
Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis :A randomized controlled trial[J]. JAMA, 2001; 285(21): 2719-2728.
|
| 8. |
Marin R, Ruilope LM, Aljama P, Aranda P, Segura J, Diez J; Investigators of the ESPIRAL Study. Efecto del tratamiento antihipertensivo Sobre la Progresion de la Insuficiencia RenAL en pacientes no diabeticos. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease[J]. J Hypertens, 2001; 19(10): 1871-1876.
|
| 9. |
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J]. N Engl J Med, 2001, 345(12): 861-869.
|
| 10. |
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotension-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J]. N Engl J Med, 2001; 345(12): 851-860.
|
| 11. |
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trail[J]. Lancet, 2003; 361(9352): 117-124.
|
| 12. |
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin[J]. N Engl J Med, 1998; 339(9): 584-590.
|
| 13. |
National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic renal disease: update 2000[J]. Am J Kidney Dis, 2001; 37(Suppl 1): S182-S238.
|
| 14. |
Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group The EBPG Ⅱ Working Group. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure[J]. Nephrol Dial Transplant, 2004; 19(Suppl 2): ii1-ii47.
|
| 15. |
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease[J]. Engl J Med, 1994; 330(13): 877-884.
|
| 16. |
Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown[J]? J Am Soc Nephrol, 1999; 10(11): 2426-2439.
|
| 17. |
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal disease: A meta-analysis[J]. Ann Intern Med, 1996; 124(7): 627-632.
|
| 18. |
Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure[J]. Nephrol Dial Transplant, 2000; 15(12): 1986-1992.
|
| 19. |
Kasiske BL, Lakatua JD. The effects of dietary protein restriction on chronic progressive renal disease[J]. Miner Electrolyte Metab, 1997; 23(3-6): 296-300.
|
